Cargando…

Comment on “Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis”

Detalles Bibliográficos
Autores principales:	Mo, Han-Yue, Xiang, Bang-De, Zhong, Jian-Hong, Li, Le-Qun, You, Xue-Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963590/ https://www.ncbi.nlm.nih.gov/pubmed/27500539 http://dx.doi.org/10.1155/2016/7625982

Ejemplares similares

Response to: Comment on “Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis”
por: Yuan, Peng, et al.
Publicado: (2016)

Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis
por: Yuan, Peng, et al.
Publicado: (2016)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma
por: Yu, Liang-He, et al.
Publicado: (2011)

Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy
por: Mo, Han-Yue, et al.
Publicado: (2017)

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy
por: Ke, Yang, et al.
Publicado: (2013)

Systematic review of treatment strategy for recurrent hepatocellular carcinoma: Salvage liver transplantation or curative locoregional therapy
por: Wang, Hong-Liang, et al.
Publicado: (2019)

Comment on: ‘Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade'
por: Cucchetti, Alessandro, et al.
Publicado: (2016)

Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
por: Chen, Jian-Lin, et al.
Publicado: (2016)

Reply to: Comment on: ‘Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade'
por: Johnson, Philip, et al.
Publicado: (2016)

Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy
por: Zhu, Dong-Mei, et al.
Publicado: (2020)

SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain
por: Lens, Sabela, et al.
Publicado: (2020)

Comment on “Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis”
por: Tang, Xiao-Long, et al.
Publicado: (2022)

Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients
por: Kim, Sehwa, et al.
Publicado: (2021)

Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative
por: Wang, Kai, et al.
Publicado: (2018)

Antiviral therapy of chronic HBV infection in pregnancy
por: Nikolajuk-Stasiuk, Julita, et al.
Publicado: (2016)

Effects of Antiviral Therapy on the Recurrence of Hepatocellular Carcinoma After Curative Resection or Liver Transplantation
por: Du, Yan, et al.
Publicado: (2012)

Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy
por: Nam, Joon Yeul, et al.
Publicado: (2020)

Update on Antiviral Therapies
por: Wilkes, Rebecca P., et al.
Publicado: (2016)

HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection
por: Liao, Rui, et al.
Publicado: (2018)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy
por: Qian, Xiangjun, et al.
Publicado: (2020)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Obesity Does Not Influence Outcomes in Hepatocellular Carcinoma Patients following Curative Hepatectomy
por: Guo, Zhe, et al.
Publicado: (2015)

Comment on a meta-analysis comparing hepatic resection or transarterial chemoembolization as initial treatment for hepatocellular carcinoma
por: Zhong, Jian-Hong, et al.
Publicado: (2015)

Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
por: Liu, Jian, et al.
Publicado: (2023)

Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy
por: Mazzaro, Cesare, et al.
Publicado: (2022)

Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma
por: Chen, Kang, et al.
Publicado: (2022)

Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy
por: Liu, Shousheng, et al.
Publicado: (2021)

Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis
por: Liu, Kai-Xuan, et al.
Publicado: (2021)

Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis
por: Xu, Mingxing, et al.
Publicado: (2019)

Comment on: Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients
por: Akbulut, Sami, et al.
Publicado: (2021)

Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma
por: Dai, Xiao-Meng, et al.
Publicado: (2017)

Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure
por: Yoo, Joseph, et al.
Publicado: (2018)

Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy
por: Li, Ziqiang, et al.
Publicado: (2022)

1248. Relationship Between ALT and New HBV Biomarkers in HBV/HIV Coinfected Persons Started on Antiviral Therapy
por: Rouster, Susan D, et al.
Publicado: (2022)

Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus
por: Zhou, Jing, et al.
Publicado: (2021)

Corrigendum to “Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma”
por: Dai, Xiao-Meng, et al.
Publicado: (2017)

Cautious optimism in anticipation of hepatitis B curative therapies
por: Turshudzhyan, Alla, et al.
Publicado: (2022)

Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy
por: Frankul, Leana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hn04q72skjegut3abd5dhhavg4